Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
Oncology. 2011;81 Suppl 1:152-7. doi: 10.1159/000333279. Epub 2011 Dec 22.
Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) were reported. Thereafter, only a relatively small number of CR cases were reported worldwide for sorafenib therapy. We herein report a case of CR in a patient treated with sorafenib for 4 months. The patient had advanced HCC with multiple lung metastases, and there has been no recurrence after 8 months following cessation of administration. To our knowledge, this is the first time a female treated with sorafenib alone for HCC has had a CR.
索拉非尼是一种口服多激酶抑制剂，已在晚期肝细胞癌（HCC）患者中显示出临床疗效。然而，在 SHARP 试验（索拉非尼 HCC 评估随机协议试验）和亚太地区试验（在亚太地区进行）中，均未报告完全缓解（CR）病例。此后，在全球范围内，仅有少数接受索拉非尼治疗的患者报告了 CR 病例。我们在此报告了 1 例接受索拉非尼治疗 4 个月后达到 CR 的病例。该患者患有晚期 HCC 伴多发肺转移，停药 8 个月后无复发。据我们所知，这是首例单独接受索拉非尼治疗 HCC 的女性患者达到 CR。
